Advertisement
Canada markets open in 53 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7300
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    83.27
    +0.46 (+0.56%)
     
  • Bitcoin CAD

    87,664.49
    -3,635.57 (-3.98%)
     
  • CMC Crypto 200

    1,362.94
    -19.64 (-1.42%)
     
  • GOLD FUTURES

    2,339.10
    +0.70 (+0.03%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6600
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,471.75
    -192.75 (-1.09%)
     
  • VOLATILITY

    16.34
    +0.37 (+2.32%)
     
  • FTSE

    8,103.08
    +62.70 (+0.78%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     

Will Jazz Pharma's Stock Awake With Q2 Earnings?

With Q2 earnings due Aug. 5, Jazz Pharmaceuticals is testing a new buy point. The maker of narcolepsy-related treatment Xyrem is in the No. 7-ranked Medical - Ethical Drugs industry group, which also includes top-rated drugmakers Horizon Pharmaceuticals and Valeant Pharmaceuticals.